Grabar Law Office Continues to Investigate Claims on Behalf of Long-Term Shareholders of Verrica Pharmaceuticals, Inc. (VRCA)

Philadelphia, Pennsylvania--(Newsfile Corp. - October 8, 2024) - Current Verrica Pharmaceuticals, Inc. (NASDAQ: VRCA) shareholders who have held Verrica shares since prior to May 19, 2021, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever. Click here to learn more: https://grabarlaw.com/the-latest/verrica-shareholder-investigation/

Why: On September 3, 2024, a Federal Court issued an Order denying Verrica Defendants' Motion to Dismiss a securities fraud class action complaint. That complaint alleges that Verrica Pharmaceuticals, Inc., via certain of its officers and directors, made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, the Complaint alleges Defendants failed to disclose to investors: (1) that there were manufacturing deficiencies at the facility where Verrica's contract manufacturer produced bulk solution for VP-102; (2) that these deficiencies were not remediated when Verrica resubmitted its NDA for VP-102 for molluscum; (3) that the foregoing presented significant risks to Verrica obtaining regulatory approval of VP-102 for molluscum; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

What You Can Do: Current Verrica (NASDAQ: VRCA) shareholders who have held Verrica stock since prior to May 19, 2021, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever.

If you would like to learn more about this matter, you are encouraged to visit https://grabarlaw.com/the-latest/verrica-shareholder-investigation/, contact us at jgrabar@grabarlaw.com, or call 267-507-6085.

Attorney Advertising Disclaimer

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/225980